Related Experiment Video
Updated: Mar 25, 2026
06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
6.2K
Microsatellite Instability as a Biomarker for PD-1 Blockade
Jonathan C Dudley1, Ming-Tseh Lin2, Dung T Le3
1Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Summary
Microsatellite instability (MSI) predicts positive responses to anti-PD-1 inhibitors in patients with advanced cancers. MSI testing offers a valuable biomarker for precision medicine, guiding immunotherapy selection for improved patient outcomes.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Microsatellite instability (MSI) is linked to increased mutations and neoepitope formation, potentially enhancing immunotherapy response.
- Previous research indicates MSI cancers show significant responses to anti-PD-1 inhibitors, especially in patients refractory to conventional treatments.
- MSI arises from DNA mismatch repair (MMR) gene defects (Lynch syndrome) or MLH1 promoter hypermethylation.
Purpose of the Study:
- To review the pathogenesis, prognostic significance, and diagnostic methods for MSI.
- To assess the frequency of MSI across various tumor types.
- To evaluate MSI as a predictive biomarker for anti-PD-1 blockade therapy.
Main Methods:
- Review of existing literature on MSI, immunotherapy, and diagnostic techniques.
- Analysis of MSI frequency data across different cancer types.
- Discussion of diagnostic guidelines including PCR and immunohistochemistry for MMR proteins.
Main Results:
- MSI cancers exhibit a 10- to 100-fold increase in mutation rates.
- Colorectal and endometrial cancers show higher MSI frequencies (20% and 22%-33%, respectively) compared to others.
- Diagnostic approaches have advanced from clinical criteria to molecular and protein-based tests.
Conclusions:
- MSI is a significant biomarker for predicting response to anti-PD-1 inhibitors.
- MSI testing can be integrated into precision medicine strategies.
- Further validation may expand the role of MSI testing in cancer treatment selection.
